Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tioga Cardiovascular

Request full access

Tioga Medical Center Where our patients come first

Campbell, United StatesFounded 2012Health Tech & Medtech

About Tioga Cardiovascular

Operating from Los Gatos, California, Tioga Cardiovascular functions as a portfolio company of the medical innovation hub Shifamed. The company was co-founded in 2012 by Amr Salahieh and Mike Dineen. Salahieh, the founder of Shifamed, is a seasoned entrepreneur in the medical device sector with a background in biomedical and electrical engineering and a history of creating and exiting successful companies like Sadra Medical and Embolic Protection, Inc. Dineen, who serves as President and CEO, brings over 30 years of MedTech experience, particularly with startups, and has a history of leading Shifamed portfolio companies like Kalila Medical through to acquisition.

Tioga Cardiovascular is focused on the structural heart market, specifically addressing mitral regurgitation (MR), a condition where the mitral valve fails to close properly, affecting millions. The company's core business revolves around the development and eventual commercialization of transcatheter mitral valve replacement (TMVR) systems. This market serves patients who are often too ill to undergo traditional open-heart surgery. Tioga's business model is centered on creating a less invasive, procedurally simpler valve replacement that can be delivered via catheter, aiming for acquisition by a larger medical device company upon reaching key milestones, a model successfully employed by its parent incubator, Shifamed.

The company's primary product under development is the Luna™ TMVR system. This system is designed for transseptal delivery, a less invasive approach to reach the mitral valve. Key features of the Luna™ system include a unique valve and anchor design made from nitinol and a compact delivery profile (28 Fr. ), engineered to minimize obstruction of the left ventricular outflow tract (LVOT) and reduce the number of patients excluded from treatment due to anatomical constraints. The aim is to provide a more adaptable solution for patients with both degenerative and functional MR. Tioga has progressed its technology through multiple funding rounds, including a $15M Series A in 2019, a $30M Series B in 2021, and a $30M Series C in 2023, bringing total funding to over $75M. A significant achievement was the announcement of the first-in-human implantations of the Luna™ system in October 2024.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
58.7/100
Industry
Health
Sub-industry
Medical Devices
Sector
medical implants, Cardiology and cardiovascular, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B, B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Sep 2025 $0 — Undisclosed ↗
SERIES COther financing Feb 2023 $30M $120M PA MedTech VC Fund · The Capital Partnership · AMED Ventures · Shifamed Angels ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Tioga Cardiovascular website traffic

Latest recorded traffic for Tioga Cardiovascular is 1.4K monthly website visits, up 84.2% over the last three months. Tioga Cardiovascular's team declined 31.3% over the past year.

Latest monthly visits1.4K 3-month web change+84.2% 1-year team growth-31.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tioga Cardiovascular in the Campbell ecosystem

Live from Dealroom

The Tioga Cardiovascular office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • PA MedTech VC Fund
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States92.9%
🇬🇧 United Kingdom7.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tioga Cardiovascular on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tioga Cardiovascular’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.